Friday, July 10, 2026
🇺🇸 FDA

pharma · Schizophrenia · Autosomal Recessive Polycystic Kidney Disease

Otsuka Beijing Research

Otsuka Beijing Research Institute

Otsuka Beijing Research trial registry — 35 ClinicalTrials.gov studies with program phase, status, and indication context.

CN HQ
NMPA registrant Type
Company details
Status
Public
HQ
CN
Programs
33
Drugs
25
Patents
0
All projects Drug pipeline News & analysis

Recent coverage

View all news & analysis →
Intelligence · Clinical Trials

Otsuka Beijing Research clinical trials

Registry index of 35 ClinicalTrials.gov studies linked to Otsuka Beijing Research programs — each row shows trial ID, program name, phase, status, and indication.

Otsuka Beijing Research trial registry — 35 ClinicalTrials.gov studies with program phase, status, and indication context.

Recent trial activity

8 updates

Latest clinical program signals indexed for Otsuka Beijing Research.

  1. 20-AVP-786-306 — Phase 3

    Clinical update

  2. 156-201-00307 — Phase 3

    Clinical update

  3. VIS171-103 — Phase 1

    Clinical update

  4. JNT517-301 — Phase 3

    Clinical update

  5. 323-201-00009 — Phase 1

    Clinical update

  6. Tolvaptan — Approved

    Clinical update

  7. Tolvaptan 15mg or 30mg or 60mg or Placebo — Phase 1

    Clinical update

  8. Escitalopram — Phase 3

    Clinical update

Trial registry

35 studies

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.